Bicycle Therapeutics (BCYC) Net Equity Issued and Repurchased (2021 - 2024)
Bicycle Therapeutics' (BCYC) quarterly Net Equity Issued and Repurchased came in at -$979000.0 in Q3 2024, down 105.05% YoY from $19.4 million in Q4 2023, and down 9890.0% on a QoQ basis from $10000.0 in Q4 2023.
Bicycle Therapeutics (BCYC) Net Equity Issued and Repurchased (2021 - 2024) Analysis & Trends
Bicycle Therapeutics (BCYC) has 3 years of Net Equity Issued and Repurchased data on file, last reported at -$979000.0 in Q3 2024.
- Quarterly Net Equity Issued and Repurchased fell 105.05% year-over-year to -$979000.0 in Q3 2024, while the trailing twelve-month figure through Dec 2024 was $18.4 million (down 46.15% YoY) and the FY2024 annual result came in at $544.1 million, up 118.22% from the prior year.
- Net Equity Issued and Repurchased slipped to -$979000.0 in Q3 2024, from $10000.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $188.4 million in Q4 2021 to a low of -$979000.0 in Q3 2024.
- A 3-year average of $35.9 million and a median of $12.1 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 105.05% in 2024, down 105.05% in 2024.
- Tracing BCYC's Net Equity Issued and Repurchased over 3 years: stood at $188.4 million in 2021, then plunged by 99.99% to $10000.0 in 2023, then plunged by 9890.0% to -$979000.0 in 2024.
- The last three Net Equity Issued and Repurchased figures came in at -$979000.0 (Q3 2024), $10000.0 (Q4 2023), and $19.4 million (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -979,000.00 |
| Sep 30, 2024 | -979,000.00 |
| Dec 31, 2023 | 10,000.00 |
| Dec 31, 2023 | 10,000.00 |
| Sep 30, 2023 | 19.40 Mn |
| Sep 30, 2023 | 19.40 Mn |
| Jun 30, 2023 | 12.10 Mn |
| Jun 30, 2023 | 12.10 Mn |
| Mar 31, 2023 | 2.72 Mn |
| Mar 31, 2023 | 2.72 Mn |
| Dec 31, 2021 | 188.39 Mn |
| Dec 31, 2021 | 188.39 Mn |
| Sep 30, 2021 | 29.84 Mn |
| Sep 30, 2021 | 29.84 Mn |